GIC和Temasek在临床研究公司Novotech获得重大股权,价值超过30亿美元。 GIC and Temasek acquire a significant stake in clinical research firm Novotech, valued at over $3 billion.

新加坡主权财富基金GIC和Temasek在一家临床研究公司Novotech获得重大股份,TPG也进行再投资。 GIC and Temasek, Singapore's sovereign wealth funds, have acquired a significant stake in Novotech, a clinical research firm, with TPG also reinvesting. 这项交易价值超过30亿美元, 目的是加速该公司的全球扩张, 特别是在亚太、美国和欧洲。 The deal, valuing Novotech at over $3 billion, aims to accelerate the company's global expansion, particularly in Asia-Pacific, US, and Europe. 新科技拥有30多个办事处,专门从事生物技术和小型制药公司的临床试验。 Novotech, with over 30 offices, specializes in clinical trials for biotech and small pharmaceutical companies.